Sanofi in Ireland
Our manufacturing campus in Waterford has more than 740 skilled people working across multiple products and platforms, supplying therapies to people in over 70 countries. We continue to expand, providing opportunities for people to join the team, and help us support our No1 stakeholders; the people we provide our medicines for.
Our dedicated team based out of Dublin bring a broad range of treatments to people across Ireland. Amongst our treatments we have consumer healthcare, vaccines, and medicines for cardiovascular disease, diabetes, multiple sclerosis, thrombosis, rare diseases and atopic dermatitis.
Transparency in our interactions
Under our obligations to the EFPIA Disclosure Code and the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice, we list all transfers of value (payments which can be direct, indirect or in kind) made to healthcare organisations and individual HCPs on the IPHA Transfers of Value site. In order to comply with data protection legislation, the transfers of value made to individual HCPs is only disclosed if they provide consent. Transfers of value made to HCPs who have not consented will be placed in an aggregated pool.
Our annual breakdown of transfers of value to patient associations is posted on Sanofi.com
Committing to our communities
The Waterford team support a range of programmes to promote study and careers in STEM (science, technology, engineering and maths) subjects and is a long-standing partner of Junior Achievement Ireland who unite business and education. We also champion diversity, including through Sanofi Future Female Leaders Scholarships, and play an active role in the Waterford community, most notably taking part in the city’s renowned international street theatre festival with the Sanofi Spraoi Orchestra.
As well as supporting various causes in the community around our Citywest base, the Dublin team work closely with CMRF Crumlin who support Our Lady’s Children’s Hospital and the National Children’s Research Centre.
Valproate Educational materials
These materials contain important information about the risks associated with valproate (Epilim) in female children, women of childbearing potential and pregnant women. They were developed in agreement with the Health Products Regulatory Authority (HPRA), formerly the Irish Medicines Board, and are available to healthcare professionals and patients.
Suspected adverse events should be reported to HPRA via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2;
Tel: +353 1 6764971; Fax: +353 1 6762517.
You can also report adverse reactions direct to Sanofi on IEPharmacovigilance@sanofi.com or + 353 1 403 5600.
You can contact our medical information team for further information at IE-Medicalinformation@sanofi.com or + 353 1 403 5600.
Donations to charity
If you represent a charitable organisation and wish to request financial support for an activity or project please submit your request here